Robert L. Coleman, MD, FACOG, FACS, discusses the potential of tisotumab vedotin in cervical cancer.
Robert L. Coleman, MD, FACOG, FACS, chief scientific officer of The US Oncology Network, discusses the potential of tisotumab vedotin in cervical cancer.
Findings from the phase 2 innovaTV 204 trial, which were presented during the 2020 ESMO Virtual Congress, showed a 24% objective response rate with tisotumab vedotin, an investigational antibody-drug conjugate (ADC), in patients with recurrent and/or metastatic cervical cancer who received prior doublet chemotherapy and bevacizumab (Avastin) if eligible.
The study met its primary end point. The next steps with tisotumab vedotin include pursuing regulatory approval through the FDA’s accelerated approval program or evaluating the ADC in a randomized phase 3 clinical trial versus chemotherapy, Coleman explains.
Additionally, because single-agent tisotumab vedotin demonstrated benefit for patients, ongoing trials are evaluating potential combination strategies with the agent plus immunotherapy and antiangiogenic agents, Coleman says. Other studies are examining tisotumab vedotin in various settings, as well as different doses of the agent. Optimal dosing and combination partners for tisotumab vedotin will become better understood with additional research, concludes Coleman.